What type of study is this?

December 8, 2025Blood

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows tocilizumab reduces graft-versus-host disease in CRS patients, indicating the need for infection monitoring.

Early use of tocilizumab shortens cytokine release syndrome duration, which impacts graft-versus-host disease.
Bacterial infections were significantly higher in patients receiving tocilizumab for CRS, underscoring monitoring needs.
Propensity score matching was applied to balance demographics and clinical characteristics of patients studied.
Tocilizumab offers a therapeutic strategy for managing CRS but may delay neutrophil engraftment in patients undergoing transplantation.

Bezerra et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark